Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4170)	3/23/2006 6:53:59 PM
From: zeta1961	Read Replies (1) \| Respond to of 12215

I listened to the CC..no sjs in the neuvigil trials..I missed how many children actually developed it..I dunno', stimulant based drugs will keep getting prescribed..perhaps it's the dosage?..they use several fold the adult Provigil dose in Sparlon. Elisabeth

To: Biomaven who wrote (4170)	3/24/2006 5:26:49 AM
From: DewDiligence_on_SI	Read Replies (2) \| Respond to of 12215

Lesson? Don't develop lifestyle drugs for children... Fortunately for CEPH, they didn’t blow much money on the Sparlon program. They gave Provigil a new name and came up with an oddball dose so it couldn’t be exactly replicated by adding and chopping Provigil tablets. And they smartly didn’t hire any salespeople, instead cutting a deal with JNJ (which is now inoperative). I’m not convinced CEPH will take this program forward, and I'm not convinced that they should take it forward: Message 22290466